Rare Thyroid Therapeutics

Company snapshot

Rare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Rare Thyroid Therapeutics. Not investment advice.

• What is Rare Thyroid Therapeutics?

  Rare Thyroid Therapeutics is a pharma organization headquartered in Stockholm, SE. Primary therapeutic focus areas include Monocarboxylate Transporter 8 (MCT8) deficiency. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from pu

• Is Rare Thyroid Therapeutics publicly traded?

  Rare Thyroid Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Rare Thyroid Therapeutics develop or market?

  We link 6 drug profile(s) where Rare Thyroid Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/rare-thyroid-therapeutics-international-ab#company-drugs.

• What are the latest developments for Rare Thyroid Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Rare Thyroid Therapeutics focus on?

  Rare Thyroid Therapeutics focuses on Monocarboxylate Transporter 8 (MCT8) deficiency based on our analysis of their pipeline programs and drug development activities.